BNF presentation directory

Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.

Chapter

Reset

Presentation	Product	Chemical substance	Chapter	Items dispensed
Glutamine 500mg capsules 091101000AAFFFF	Generic compound preparation BNF 0911010	Other amino acidandnutritional agent preparations	Nutrition and Blood	2
Glycerol 40% cream 130201000AABXBX	Generic compound emollients	Other emollient preparations	Skin	2
Glycerol 500microL/Ipecacuanha liq ext 9.8microL/5ml soln 0309020H0AAAKAK	Glycerol (Expectorant/Demulcents)	Glycerol	Respiratory System	2
Glycerol 750microlitres/5ml oral solution sugar free 0309020H0AAAHAH	Glycerol (Expectorant/Demulcents)	Glycerol	Respiratory System	2
Glycerol trioleate oil liquid 091101000AAFUFU	Generic compound preparation BNF 0911010	Other amino acidandnutritional agent preparations	Nutrition and Blood	2
Glyceryl trinitrate 50mg/50ml solution for infusion vials 0206010F0AAAVAV	Glyceryl trinitrate (Angina)	Glyceryl trinitrate	Cardiovascular System	2
Glycopyrronium bromide 0.5% in Cetomacrogol crm (Formula A) 1312000G0AAAZAZ	Glycopyrronium (Topical)	Glycopyrronium bromide	Skin	2
Glycopyrronium bromide 1% in Aqueous cream 1312000G0AAAVAV	Glycopyrronium (Topical)	Glycopyrronium bromide	Skin	2
Glycopyrronium bromide 2% in Aqueous cream 1312000G0AAAUAU	Glycopyrronium (Topical)	Glycopyrronium bromide	Skin	2
Glycopyrronium bromide 2% in Generic Unguentum M cream 1312000G0AABFBF	Glycopyrronium (Topical)	Glycopyrronium bromide	Skin	2
Glydex 160mg tablets 0601021M0BPAAAV	Glydex	Gliclazide	Endocrine System	2
Golimumab 50mg/0.5ml inj pre-filled disposable devices 1001030X0AAABAB	Golimumab	Golimumab	Musculoskeletal and Joint Diseases	2
Granisetron 2mg tablets 0406000M0AAADAD	Granisetron hydrochloride	Granisetron hydrochloride	Central Nervous System	2
Granuflex (modified) dressing 15cm x 20cm rectangular 20030400060	Granuflex (modified) dressing 15cm x 20cm rectangular	Wound Management & Other Dressings	Dressings	2
Griseofulvin 150mg/5ml oral suspension 0502050B0AAAPAP	Griseofulvin (Systemic)	Griseofulvin	Infections	2
Haddenham Doktus class 2 (23-32mmHg) armsleeve extra wide 21270000416	Haddenham Doktus class 2 (23-32mmHg) armsleeve extra wide	Lymphoedema Garments	Appliances	2
Haddenham Doktus class 3 (34-46mmHg) armsleeve 21270000423	Haddenham Doktus class 3 (34-46mmHg) armsleeve	Lymphoedema Garments	Appliances	2
Haddenham Doktus class 3 (34-46mmHg) armsleeve with grip top 21270000427	Haddenham Doktus class 3 (34-46mmHg) armsleeve with grip top	Lymphoedema Garments	Appliances	2
Haddenham Doktus class 3 (34-46mmHg) armsleeve with grip top and mitten 21270000429	Haddenham Doktus class 3 (34-46mmHg) armsleeve with grip top and mitten	Lymphoedema Garments	Appliances	2
Haddenham Doktus MTO 5cm strong lace grip top for 21270002684	Haddenham Doktus MTO 5cm strong lace grip top for	Lymphoedema Garments	Appliances	2
Haddenham Doktus MTO 5cm strong plain grip top for 21270002683	Haddenham Doktus MTO 5cm strong plain grip top for	Lymphoedema Garments	Appliances	2
Haddenham Doktus MTO class 2 (23-32mmHg) one-legged tights closed toe (DK-28) 21270002664	Haddenham Doktus MTO class 2 (23-32mmHg) one-legged tights closed toe (DK-28)	Lymphoedema Garments	Appliances	2
Haddenham Doktus MTO class 2 (23-32mmHg) one-legged tights closed toe (DK-29) 21270002663	Haddenham Doktus MTO class 2 (23-32mmHg) one-legged tights closed toe (DK-29)	Lymphoedema Garments	Appliances	2
Haddenham Doktus MTO class 2 (23-32mmHg) thigh length closed toe with waist attachment (DK-25) 21270002660	Haddenham Doktus MTO class 2 (23-32mmHg) thigh length closed toe with waist attachment (DK-25)	Lymphoedema Garments	Appliances	2
Haddenham Doktus MTO class 3 (34-46mmHg) tights closed toe 21270002672	Haddenham Doktus MTO class 3 (34-46mmHg) tights closed toe	Lymphoedema Garments	Appliances	2

Why monitor BNF codes?

Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.

Track cost pressure

Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.

Understand demand drivers

Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.